A phase III, randomized, double-blind, placebo-controlled study of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated subjects with locally advanced or metastatic, nonsquamous, non-small cell lung cancer (NSCLC) .
A. Sandler
No relevant relationships to disclose
J. H. Schiller
Consultant or Advisory Role - Daiichi Sankyo
V. Hirsh
No relevant relationships to disclose
L. V. Sequist
Consultant or Advisory Role - ArQule (U)
J. Soria
No relevant relationships to disclose
J. Von Pawel
Consultant or Advisory Role - Daiichi Sankyo
Q. Wang
Employment or Leadership Position - Daiichi Sankyo
A. U. Pande
Employment or Leadership Position - Daiichi Sankyo
B. E. Schwartz
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
E. G. Garmey
Employment or Leadership Position - ArQule
Stock Ownership - ArQule
I. Gorbatchevsky
Employment or Leadership Position - Daiichi Sankyo
G. Scagliotti
Honoraria - Roche